Pharmaceutical Mergers and Acquisitions

Abstract

Pharmaceutical Mergers and Acquisitions guides you to build an M&A plan that focuses on key goals, avoids costly mistakes, and realizes deal potential as quickly as possible. CEI designed this study to identify the primary drivers of M&A activity. Through the input of pharma industry leaders, our study provides solutions to the greatest M&A pitfalls and gives clear, detailed insight of trends in pharmaceutical deals. The result: a roadmap to the M&A landscape.

The past year has been marked by heightened M&A activity among companies of all sizes. Small companies are increasingly investing in large-molecule products that are expensive to produce and test in clinical trials - but in this tough economic climate, they face diminishing capital and the threat of closing. To continue their work on time-sensitive compounds, they are exploring the possibility of a company sale. On the other hand, for those companies with cash, this situation presents an opportunity to acquire attractive compounds and technology platforms at a discount.

Timelines, rankings, strategies, and deal profiles will allow you to maximize the benefits and growth opportunities of a deal:

Understand the M&A environment

Learn what is driving the acquisition strategies of top companies - and how other organizations are seeking suitors for their own sales.

Build a competitive deal-making process

• Target the right deals with an M&A task force
• Implement a timeline that works for both sides
• Track different types of financing across deals brokered by companies of different sizes

Complete the integration as soon as possible -- and boost productivity

• Build an integration timeline
• Clarify roles and responsibilities in the new organization
• Reduce the impact of attrition

Learn from the recent past

We' ve vetted the top 75 deals of 2009 to determine purchasing trends, including:

• Price/pipeline ratios
• Financing options
• Deal motivators

Look into the future of M&A

Gather perspectives and predictions on future deals from the managers who execute them.

Compare your deal to others

• Use the deal profiles to compare metrics for 19 different deals
• Explore deal size, functional involvement in deal-making, timelines, challenges and employee retention

Report Statistics

• 175 Pages
• 400+ Metrics
• 45+ Companies

• Advanced Refractive Technologies
• Anavex
• ApotheCom
• AstraZeneca
• Bristol-Myers Squibb
• Centocor
• Ethypharm
• Galderma
• IBA
• Lyotropic Therapeutics
• Metabolex
• Novagali Pharma
• Novartis
• Novex Pharmaceuticals
• NPS Pharmaceuticals
• OCO Biomedical
• Orion Corporation
• Otsuka Pharmaceutical Co.
• Penwest
• Schering-Plough
• Strategent Life Sciences
• Talima Therapeutics
• UCB
• Vivabiocell